1. Incidence of virological failure and emergence of resistance with twice‐daily vs every 8‐h administration of telaprevir in the OPTIMIZE study. Issue 12 (December 2014) Authors: Dierynck, I.; Ghys, A.; Witek, J.; Luo, D.; Janssen, K.; Daems, B.; Picchio, G.; Buti, M.; De Meyer, S. Journal: Journal of viral hepatitis Issue: Volume 21:Issue 12(2014) Page Start: 835 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study. Issue 1 (3rd October 2016) Authors: Fevery, B.; Verbinnen, T.; Peeters, M.; Janssen, K.; Witek, J.; Jessner, W.; De Meyer, S.; Lenz, O. Journal: Journal of viral hepatitis Issue: Volume 24:Issue 1(2017) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗